Curanex Pharmaceuticals Court & Legal Update
Curanex Pharmaceuticals disclosed two putative securities class action lawsuits filed in the Supreme Court of the State of New York related to its August 2025 IPO. The complaints allege material misstatements and omissions in the IPO offering documents regarding risks of stock-price manipulation and underwriter due diligence deficiencies. The company intends to defend the actions vigorously and has received extensions to respond to the complaints through late 2026.
- Counterparty
- Daymond Morales and Robert Lovett